PPARA and metabolic dysfunction-associated steatotic liver disease: PPARs are a group of NRs that fine-tune lipid and glucose metabolism and regulate inflammation and fibrosis (Pawlak et al., 2015; Dubois et al., 2017); besides fibrates, PPARα ligands, show anti-steatogenic activity in animal models of NAFLD and inhibit adipocyte hypertrophy and insulin resistance inducing fatty acid β-oxidation in adipose tissue (Monk and Todd, 1987; Schoonjans et al., 1996; Fruchart et al., 1998; Jeong and Yoon, 2009), small pilot NASH studies did not show convincing efficacy (Laurin et al., 1996).